| (Values in U.S. Thousands) | Sep, 2012 | Sep, 2011 | Sep, 2010 | Sep, 2009 | Sep, 2008 |
| Sales | 4,050 | 3,960 | 10,460 | 10,560 | 15,920 |
| Sales Growth | +2.27% | -62.14% | -0.95% | -33.67% | -12.91% |
| Net Income | -4,320 | -11,550 | -47,800 | -5,260 | -60,790 |
| Net Income Growth | +62.60% | +75.84% | -808.75% | +91.35% | +20.02% |
Accentia Biopharmace (ABPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage disruptive clinical products. Accentia has a portfolio of currently marketed respiratory products and a pipeline of products in clinical development. The company's lead respiratory product candidate is SinuNase, which is under clinical development to treat chronic sinusitis. SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase three clinical trial. The Company's other lead product is BiovaxID, a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary Biovest International, Inc.
Fiscal Year End Date: 09/30